MejorAsp – sayretherapeutics

MejorAsp®

PEG L-Asparaginase Injection 3750 IU/5 mL

Sayre Therapeutics offers clinicians a PEG L-Asparaginase formulation proven to be effective in Acute Lymphoblastic Leukemia (ALL).

Indication

MejorAsp^® is indicated as a component of a multi agent chemotherapeutic regimen for the treatment of patients with Acute Lymphoblastic Leukemia who are hypersensitive to asparaginase.

Formulation

PEG L-Asparaginase Injection 3750 IU for intravenous or intramuscular administration.

MejorAsp®

Offers lower dosing across longer intervals i. e. 2500 IU/sq. mt. every 14 days.
Offers slower clearance from plasma with lesser half life (6 days), hence lesser allergic reactions.
Reduces risk of high titre Antibodies (Abs) formation, hence no loss of enzyme activity.

MejorAsp^® is manufactured by a US FDA approved biotechnology plant that is Certified by: WHO-GMP and ISO 9000:2001, Therapeutic Goods Administration, Australia (TGA) and by the European Union’s Certificate Of Suitability (COS).

MejorAsp®

PEG L-Asparaginase Injection 3750 IU/5 mL

Quick Link

Get in Touch

MejorAsp®

PEG L-Asparaginase Injection 3750 IU/5 mL

Quick Link

Get in Touch

Contact Us